131 related articles for article (PubMed ID: 15723258)
1. Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma.
O'Reilly T; Wartmann M; Maira SM; Hattenberger M; Vaxelaire J; Muller M; Ferretti S; Buchdunger E; Altmann KH; McSheehy PMJ
Cancer Chemother Pharmacol; 2005 Apr; 55(4):307-317. PubMed ID: 15723258
[TBL] [Abstract][Full Text] [Related]
2. Carvedilol in glioma treatment alone and with imatinib in vitro.
Erguven M; Yazihan N; Aktas E; Sabanci A; Li CJ; Oktem G; Bilir A
Int J Oncol; 2010 Apr; 36(4):857-66. PubMed ID: 20198329
[TBL] [Abstract][Full Text] [Related]
3. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake.
Pietras K; Stumm M; Hubert M; Buchdunger E; Rubin K; Heldin CH; McSheehy P; Wartmann M; Ostman A
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3779-87. PubMed ID: 14506171
[TBL] [Abstract][Full Text] [Related]
4. Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo.
O'Reilly T; McSheehy PM; Wenger F; Hattenberger M; Muller M; Vaxelaire J; Altmann KH; Wartmann M
Prostate; 2005 Nov; 65(3):231-40. PubMed ID: 15948135
[TBL] [Abstract][Full Text] [Related]
5. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
Ren H; Tan X; Dong Y; Giese A; Chou TC; Rainov N; Yang B
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):241-52. PubMed ID: 19159435
[TBL] [Abstract][Full Text] [Related]
6. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.
Decaudin D; de Cremoux P; Sastre X; Judde JG; Nemati F; Tran-Perennou C; Fréneaux P; Livartowski A; Pouillart P; Poupon MF
Int J Cancer; 2005 Feb; 113(5):849-56. PubMed ID: 15499612
[TBL] [Abstract][Full Text] [Related]
7. Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer.
Corcoran NM; Costello AJ
BJU Int; 2005 Sep; 96(4):640-6. PubMed ID: 16104925
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy using imatinib and vatalanib improves the therapeutic efficiency of paclitaxel towards a mouse melanoma tumor.
Kłosowska-Wardęga A; Hasumi Y; Åhgren A; Heldin CH; Hellberg C
Melanoma Res; 2011 Feb; 21(1):57-65. PubMed ID: 20975605
[TBL] [Abstract][Full Text] [Related]
9. Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model.
Sumida T; Kitadai Y; Shinagawa K; Tanaka M; Kodama M; Ohnishi M; Ohara E; Tanaka S; Yasui W; Chayama K
Int J Cancer; 2011 May; 128(9):2050-62. PubMed ID: 21387285
[TBL] [Abstract][Full Text] [Related]
10. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Reardon DA; Desjardins A; Vredenburgh JJ; Sathornsumetee S; Rich JN; Quinn JA; Lagattuta TF; Egorin MJ; Gururangan S; McLendon R; Herndon JE; Friedman AH; Salvado AJ; Friedman HS
Neuro Oncol; 2008 Jun; 10(3):330-40. PubMed ID: 18359865
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts.
Bertino P; Piccardi F; Porta C; Favoni R; Cilli M; Mutti L; Gaudino G
Clin Cancer Res; 2008 Jan; 14(2):541-8. PubMed ID: 18223230
[TBL] [Abstract][Full Text] [Related]
12. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.
Hofstetter B; Vuong V; Broggini-Tenzer A; Bodis S; Ciernik IF; Fabbro D; Wartmann M; Folkers G; Pruschy M
Clin Cancer Res; 2005 Feb; 11(4):1588-96. PubMed ID: 15746064
[TBL] [Abstract][Full Text] [Related]
13. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma.
Kim R; Emi M; Arihiro K; Tanabe K; Uchida Y; Toge T
Cancer; 2005 May; 103(9):1800-9. PubMed ID: 15786421
[TBL] [Abstract][Full Text] [Related]
14. ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells.
Declèves X; Bihorel S; Debray M; Yousif S; Camenisch G; Scherrmann JM
Pharmacol Res; 2008 Mar; 57(3):214-22. PubMed ID: 18337118
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Cortes J; Jabbour E; Daley GQ; O'Brien S; Verstovsek S; Ferrajoli A; Koller C; Zhu Y; Statkevich P; Kantarjian H
Cancer; 2007 Sep; 110(6):1295-302. PubMed ID: 17623836
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate reduces rituximab-induced tumor-growth inhibition in vivo on Epstein-Barr virus-associated human B-cell lymphoma.
Némati F; Mathiot C; Grandjean I; Lantz O; Bordier V; Dewulf S; Ekue R; Di Santo JP; Poupon MF; Decaudin D
Anticancer Drugs; 2007 Oct; 18(9):1029-37. PubMed ID: 17704653
[TBL] [Abstract][Full Text] [Related]
17. Continuous low-dose infusion of patupilone increases the therapeutic index in mouse and rat tumour models.
Becquet M; Laborde L; Texier C; Sterker D; Gschwind HP; Pfaar U; Wartmann M; O'Reilly TM; McSheehy PM
Anticancer Drugs; 2018 Aug; 29(7):691-701. PubMed ID: 29734209
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
19. The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells.
Oehler C; von Bueren AO; Furmanova P; Broggini-Tenzer A; Orlowski K; Rutkowski S; Frei K; Grotzer MA; Pruschy M
Neuro Oncol; 2011 Sep; 13(9):1000-10. PubMed ID: 21743064
[TBL] [Abstract][Full Text] [Related]
20. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Reardon DA; Egorin MJ; Desjardins A; Vredenburgh JJ; Beumer JH; Lagattuta TF; Gururangan S; Herndon JE; Salvado AJ; Friedman HS
Cancer; 2009 May; 115(10):2188-98. PubMed ID: 19248046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
